BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget 2016;7:85450-63. [PMID: 27863427 DOI: 10.18632/oncotarget.13398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Tyan YS, Lee YP, Chuang HY, Wang WH, Hwang JJ. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model. Biosci Rep 2021;41:BSR20204203. [PMID: 33974005 DOI: 10.1042/BSR20204203] [Reference Citation Analysis]
2 Saber S, Ghanim AMH, El-ahwany E, El-kader EMA. Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis. Cancer Chemother Pharmacol 2020;85:331-43. [DOI: 10.1007/s00280-020-04033-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
3 Chen T, Yu Q, Xin L, Guo L. Circular RNA circC3P1 restrains kidney cancer cell activity by regulating miR-21/PTEN axis and inactivating PI3K/AKT and NF- kB pathways. J Cell Physiol 2020;235:4001-10. [PMID: 31643094 DOI: 10.1002/jcp.29296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
4 Weng MC, Li MH, Chung JG, Liu YC, Wu JY, Hsu FT, Wang HE. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Biomed Pharmacother 2019;116:109032. [PMID: 31163381 DOI: 10.1016/j.biopha.2019.109032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
5 Liu R, Zhao D, Zhang X, Han S, Yang Y, Ma J, Meng D. A20 enhances the radiosensitivity of hepatocellular carcinoma cells to 60Co-γ ionizing radiation. Oncotarget 2017;8:93103-16. [PMID: 29190981 DOI: 10.18632/oncotarget.21860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
6 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chuang HY, Tyan YS, Hwang JJ, Shih KC, Lin WC. A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model. Oncol Lett 2021;21:337. [PMID: 33692869 DOI: 10.3892/ol.2021.12598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 14.4] [Reference Citation Analysis]
9 Fu L, Guo L, Zheng Y, Zhu Z, Zhang M, Zhao X, Cui H. Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells. Oncol Lett 2018;15:5081-6. [PMID: 29552141 DOI: 10.3892/ol.2018.7933] [Reference Citation Analysis]
10 Tan W, Luo X, Li W, Zhong J, Cao J, Zhu S, Chen X, Zhou R, Shang C, Chen Y. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine 2019;40:446-56. [PMID: 30594557 DOI: 10.1016/j.ebiom.2018.12.047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
11 Fiore M, D Apos Angelillo RM, Greco C, Fioroni I, Ippolito E, Santini D, Ramella S. Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer. Chemotherapy 2018;63:83-9. [PMID: 29554654 DOI: 10.1159/000488252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
13 Lee KC, Chen WT, Liu YC, Lin SS, Hsu FT. Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-ĸB Activation. In Vivo 2018;32:1097-103. [PMID: 30150431 DOI: 10.21873/invivo.11351] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
14 Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, Nishimura R, Tada H, Miyagi S, Ishida T, Unno M, Kamei T, Gonda K. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol 2021;38:60. [PMID: 33881631 DOI: 10.1007/s12032-021-01503-z] [Reference Citation Analysis]
15 Chen JC, Chuang HY, Liao YJ, Hsu FT, Chen YC, Wang WH, Hwang JJ. Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A. Oncol Lett 2019;17:638-45. [PMID: 30655811 DOI: 10.3892/ol.2018.9582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
16 Yu J, Wang N, Gong Z, Liu L, Yang S, Chen GG, Lai PBS. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma. Oncogene 2021;40:492-507. [PMID: 33184472 DOI: 10.1038/s41388-020-01545-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Galeaz C, Totis C, Bisio A. Radiation Resistance: A Matter of Transcription Factors. Front Oncol 2021;11:662840. [PMID: 34141616 DOI: 10.3389/fonc.2021.662840] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Chen YS, Sun R, Chen WL, Yau YC, Hsu FT, Chung JG, Tsai CJ, Hsieh CL, Chiu YM, Chen JH. The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma. In Vivo 2020;34:1789-96. [PMID: 32606148 DOI: 10.21873/invivo.11973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Mortezaee K, Najafi M, Farhood B, Ahmadi A, Shabeeb D, Musa AE. NF‐κB targeting for overcoming tumor resistance and normal tissues toxicity. J Cell Physiol 2019;234:17187-204. [DOI: 10.1002/jcp.28504] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]